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Introduction 
The field of gastrointestinal endoscopy has made great strides over the past several decades, 
and endoscopists have gained mastery over the art of advancing flexible video endoscopes in 
the upper and lower part of the gastrointestinal tract. Endoscopic evaluation of the entire 
length of the small-bowel (SB) (i.e. enteroscopy), on the other hand, poses unique challenges 
which have plagued physicians for decades. With the development of newer enteroscopic 
modalities, a more thorough evaluation is now possible. These new techniques comprise SB 
videocapsule endoscopy (VCE) and device-assisted enteroscopy (DAE); the latter includes 
double-balloon enteroscopy (DBE), single-balloon enteroscopy (SBE),  spiral enteroscopy (SE) 
and balloon-guided endoscopy (see Box). VCE has revolutionized SB imaging by providing a 
reliable and noninvasive method for complete visualization and assessment of the mucosal 
surface. Given the increased detection rate of small bowel pathology by the capsule, 
innovations in DAE have been crucial for confirmation of pathology (histologic diagnosis), 
enabling endoscopic therapy in select cases without necessitating surgery. With these recent 
advances in technology, enteroscopy currently has a pivotal role in the evaluation of patients 
with suspected SB diseases, including obscure gastrointestinal bleeding (OGIB), iron-  ȋȌǡ    ǯ  ȋȌǡ ǡ 
syndromes and celiac disease. The aim of this evidence-based and consensus based Guideline 
commissioned by the European Society of Gastrointestinal Endoscopy (ESGE) is to provide 
caregivers with a comprehensive review to guide the clinical application of enteroscopy.     
 
Methods 
The ESGE commissioned this Guideline and appointed a guideline leader (M.P.) who invited 
the listed authors to participate in the project development. The key questions were prepared 
by the coordinating team (M.P. and C.S.) and then approved by the other members. The 
coordinating team formed task force subgroups, each with its own leader, and divided the key 
topics among these task forces. Each task force performed a systematic literature search to 
prepare evidence-based and well-balanced statements on their assigned key questions (see 
Appendix e1, available online).  The coordinating team independently performed systematic 
literature searches with the assistance of a librarian. The Medline, EMBASE and Trip 
databases were searched including at minimum the following key words: VCE, DBE, SBE, SE, 
SB, and enteroscopy.  All articles studying the use of VCE and DAE in patients with OGIB, IDA, 
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CD, SB tumours, polyposis syndromes and celiac disease were selected by title or abstract. All 
selected articles were graded by the level of evidence and strength of recommendation 
according to the GRADE system [1,2]. The literature searches were updated through 
September  2014. Each task force proposed statements on their assigned key questions which 
were discussed and voted on during the plenary meeting held in November 2013. In 
September 2014, a draft prepared by the coordinating team was sent to all group members. 
After agreement on a final version, the manuscript was submitted to Endoscopy for 
publication. The journal subjected the manuscript to peer review and the manuscript was       ǯ Ǥ      
revised manuscript. This Guideline was issued in 2014 and will be considered for review and 
update in 2019 or sooner if new and relevant evidence becomes available. Any updates to the 
Guideline in the interim will be noted on the ESGE website: http://www.esge.com/esge-
guidelines.html. 
 
Recommendations and statements 
Evidence statements and recommendations are stated in italics and bold. 
 
Obscure Gastrointestinal Bleeding    
 
Statement:  The ESGE recommends VCE as the first line test in patients with OGIB (strong 
recommendation, moderate quality evidence).    
  
OGIB accounts for approximately 5% of all cases of gastrointestinal bleeding and is usually  
due to a lesion in the SB.  Studies evaluating accuracy parameters (sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV), likelihood ratios) of VCE in 
OGIB (occult and overt) patients are scarce.  However, the present evidence on diagnostic 
usefulness of VCE is enough to support the use of VCE for OGIB [3,4]. 
Accuracy parameters for VCE are not truly known because there is no standard comparative 
method.  The main reason for this is related to the lack of a reliable criterion standard to 
compare with. In this setting the ideal criterion standard would be intra-operative 
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enteroscopy (IOE).  Nevertheless, IOE carries significant mortality and morbidity (5 and 17% 
respectively) and it cannot be routinely recommended for patients with OGIB for diagnostic 
purposes [5].  In the setting of OGIB, there is only one trial reporting accuracy parameters 
comparing VCE and IOE (VCE sensitivity of 95% and a specificity of 75%) [6], a few studies 
comparing VCE with the complete SB exploration performed by  DAE, and one trial in which 
there is a combined criterion standard (including results of other procedures and/or 
outcomes during follow-up) [7-9]. For all these reasons, a diagnostic yield (DY) (i.e. rate in 
which the procedure detects what are thought to be significant findings) is typically reported 
in SB studies, as a proxy estimate of the diagnostic capability of VCE. There are limited data 
regarding differentiating OGIB as occult vs. overt subtype and thus the DY for VCE in OGIB is 
generally reported as an overall composite DY.     ǲǳ -
analysis [10]ǡǲǳ ? ?Ǥ ? ?ȋ ? ? ?ǣ ? ?Ǥ ?-76.1).  Similarly, in a ǡǤǲǳ
 ? ?Ǥ ? ?ȋ ? ? ?
CI: 57.2-63.9) [11].  Other earlier reported meta-analyses reported similar overall DYs for VCE 
in OGIB patients [12-14]. 
There have been a number clinical factors reported to be associated with a higher DY at VCE 
in patients with OGIB. Pennazio et al. reported that the highest yield at VCE was in those 
patients with active bleeding or occult bleeding (92.3% and 44.2%, respectively), whereas 
those patients with previous overt bleeding had the lowest yield (12.9%) [8]. A larger and 
more recent study confirmed that overt bleeding is the factor most strongly associated with a 
definitive diagnosis in OGIB by VCE [15]. Increased age, use of warfarin and liver co-morbidity 
seem also to be correlated with a higher VCE yield [16,17].  It was also shown in a multivariate 
analysis that an increasing number of oesophagogastroduodenoscopies (EGDs) performed 
prior to VCE examination (odds ratio [OR], 1.17; 95% CI: 1.00 Ȃ1.37), increasing transfusion 
requirements (3Ȃ9 units: OR, 1.70; 95% CI: 1.08Ȃ ?Ǥ ? ?ǡ ? ? ?ǣǡ ?Ǥ ? ?Ǣ ? ? ?ǣ ?Ǥ ? ?Ȃ 
4.37), and connective tissue disease (OR, 2.24; 95% CI: 1.14 Ȃ 4.41) were all significantly 
associated with identification of positive findings by using VCE (all p-values p<0.045) [18]. In 
patients with OGIB, VCE showed an excellent safety profile [11], thus routine SB imaging or 
the use of the PillCam® patency capsule (Covidien Plc, Dublin, Ireland) prior to VCE in these 
patients is not essential. 
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Statement: The ESGE recommends performing VCE as close as possible to the bleeding episode, 
optimally within 14 days, in order to maximize a higher diagnostic yield (strong 
recommendation, moderate quality evidence). 
 
Timing of VCE appears to be an important factor associated with significantly higher DY 
compared with delayed VCE. There are no prospective studies addressing the relationship 
between timing of VCE and DY. However, several retrospective studies, evaluating clinical 
outcome of patients with OGIB, have shown that earlier VCE contributes to an increased DY as 
compared with delayed VCE.  Two studies [8,16] addressing the higher yield of VCE with overt 
versus occult OGIB, also demonstrated that shorter intervals between the performance of VCE 
and the bleeding episode increased the DY. Katsinelos et al. [19] evaluated, whether timing of 
VCE, influences DY. In their study, the DY was 87.5% (14/16) in patients with overt bleeding 
who had VCE performed during the first 10 days following the bleeding episode, while it was 
only 1/9 (11.1%) for overt bleeders who underwent VCE more than 10 days after the 
bleeding episode. Similar results were obtained by Bresci et al. [20] who demonstrated a 
positive yield of 92% when VCE was performed within 15 days after diagnosing OGIB, 
compared to only 34% when VCE was conducted more than 15 days after diagnosis. This 
hypothesis has recently been confirmed in a group of 144 patients with overt OGIB, in whom 
early use of VCE within 3 days of hospital admission resulted in a significantly higher DY [21]. 
 
 
Statement: The ESGE recommends against PE as the first line test in OGIB patients, because of 
its lower diagnostic yield, when compared to VCE (strong recommendation, moderate quality 
evidence).   
  ǯ   ǡ  ǡ      
small bowel, the ESGE recommends performing VCE first, prior to DAE, when small bowel 
evaluation is indicated for OGIB (strong recommendation, moderate quality evidence).   
 
When comparing VCE with alternative modalities, VCE has been shown to be significantly 
superior to push enteroscopy (PE), conventional radiology, cross-sectional radiology and as 
good as DAE in evaluating and finding the lesion(s) causing the bleeding. When comparing  
ǡ ǲ ǳ
56% for VCE vs. 26% for PE, p<0.001, 95% CI: 21-38% [12,22].  However, studies used to 
populate the meta-analyses have several limitations, such as the absence of a gold standard 
 7 
modality and subjective criteria for positive findings of VCE.  There is only a single cross-over 
RCT on this topic [23].  In that study,  a definitive source of bleeding was identified in more 
patients in the VCE group than in the PE group, 50% vs. 24% overall, 43% vs. 11% SB only. 
Fewer lesions were missed by VCE than by PE. VCE missed no lesions in the SB, whereas all 
missed lesions with PE were located in the SB. Patients who started with VCE were less likely 
to require the second test than were patients who initially underwent PE.  
There has been no randomized controlled trial comparing the efficacy of VCE and DBE in 
OGIB, however four meta-analyses comparing VCE and DBE have been published, all finding 
similar results with respect to the overall DYs between the two modalities [10,13,14,24].  In 
detail, when comparing the DY of VCE to that of DAE in OGIB, the pooled DY for VCE was 
61.7% (95% CI: 47.3Ȃ76.1) and for DBE was 55.5% (95% CI: 48.9Ȃ62.1) [10].   
Although the clinical presentation may indicate the preferential endoscopic insertion route 
for DAE, VCE is also an effective tool for guiding the selection of the correct approach (oral vs 
anal approach). Even if different thresholds have been proposed, the point in time when VCE 
identifies the lesion should guide the choice of the insertion route [25,26]. 
 
 
Statement: The ESGE recommends performing VCE first, prior to small bowel radiographic 
studies and mesenteric angiography, when small bowel evaluation is indicated for OGIB (strong 
recommendation, high quality evidence). CTE may be a complementary examination to VCE in 
selected patients (weak recommendation, low quality evidence).  
 
VCE has been consistently demonstrated to be superior to SB barium radiography in patients 
with OGIB. In what appears to be the only RCT evaluating VCE vs. SB radiography in OGIB 
patients, the DY was 30% with VCE vs. 7% with dedicated SB radiography (difference 23%; 
95% CI: 11%Ȃ36%)[27]. However, the primary study endpoint of further bleeding was not 
statistically different between groups, being 30% with VCE and 24% with radiology 
(difference, 6%; 95% CI: -9% to 21%).  Previously, Triester et al. [12] performed a meta-
analysis comparing VCE vs. SB barium radiography (follow-through (SBFT) or enteroclysis) 
and reported     ǲ  ǳ    ? ? ?     ? ?  
barium radiography (p<0.001; 95% CI: 25%Ȃ48%). 
VCE is superior to mesenteric angiography/computed tomography angiography (CTA) in 
determining the cause of bleeding in patients with OGIB. In a randomized controlled trial 
comparing VCE vs. angiography, Leung et al. [28] evaluated the DY and long-term outcomes in 
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60 patients with overt OGIB. The DY for immediate VCE was significantly higher than 
angiography 53.3 % vs. 20.0 % (difference = 33.3 % , 95 % CI: 8.9 Ȃ 52.8 %). The cumulative 
risk of re-bleeding in the angiography and VCE group was 33.3 % and 16.7 %, respectively (p 
= 0.10, log-rank test). There was no significant difference in the long-term outcomes between 
the two groups including further transfusion, hospitalization for re-bleeding, and mortality.  
Furthermore, Saperas et al. [29] reported on a prospective cohort study whereby 28 
consecutive patients admitted for OGIB underwent both CTA and standard mesenteric 
angiography, followed by VCE. A source of bleeding was detected by VCE in a greater 
proportion of patients, DY 72% (95% CI: 50.6Ȃ87.9%), than CTA, 24% (95% CI: 9.4-45.1%, p 
= 0.005 vs VCE), or angiography, 56% (95% CI: 34.9Ȃ75.6%, p = NS).   
The DYs of VCE and CT-enterography (CTE) may be dependent upon the underlying causes of 
OGIB, thus CTE may be a complementary examination to VCE and could be helpful in 
determining the cause of OGIB in selected patients.  In a study by Agrawal et al. [30], 52 
patients with OGIB were prospectively enrolled to undergo VCE. CTE was then performed in 
25 patients who had no definitive source of bleeding identified at VCE.  In none of the 11 
patients with occult bleeding CTE was able to identify the source of bleeding while the DY was 
50% (7/14) in patients with obscure overt bleeding (p < 0.01), suggesting that in case of  non-
diagnostic VCE examination, CTE may be useful for detecting a source of gastrointestinal 
bleeding in patients with overt, but not occult OGIB. The supremacy of VCE when compared to 
CTE in OGIB patients was confirmed also in other studies with a DY ranging between 57-63% 
and 21-30%, respectively [31,32]. Conversely, Huprich et al. [33],  prospectively comparing 
multiphase CTE and VCE in 58 OGIB patients, reported that the sensitivity of CTE was 
significantly greater than that of VCE (88% vs 38%, respectively; p = 0.008), largely because 
CTE found more SB masses (100% vs 33%), respectively; p = 0.03).  There have been a few 
other small studies (prospective and retrospective case series) that have failed to 
demonstrate any significant difference between VCE and CTE [34-36].  
Finally, in a comparative study of 38 OGIB patients, VCE was significantly superior to 
magnetic resonance enterography/enteroclysis (MRE) for detecting abnormalities [37]. 
 
Statement: When VCE is unavailable or contraindicated, the ESGE suggests to consider DAE as 
the first diagnostic test in OGIB patients (weak recommendation, low quality evidence). When 
performed as a diagnostic test, the ESGE suggests to perform DAE as close as possible to the 
bleeding episode (weak recommendation, low quality evidence). 
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Studies evaluating accuracy parameters of PE/DAE in patients with OGIB (occult and overt) 
are scarce.  One trial used a combined criterion standard (including results of other 
procedures and/or outcomes during follow-up) to calculate sensitivity, specificity, PPV and 
NPV of DBE in the diagnoses of small-intestinal lesions in patients with OGIB,  92.7%, 96.4%, 
98.1%, and 87.1%, respectively [38]; these figures  are similar to those already known for VCE 
[8]. As with VCE, the outcome that is most frequently reported is DY.   The DY of  PE and DAE 
in OGIB patients (including both occult- and overt-OGIB patients)  is approximately 25-35% 
[39-41] and 55%, respectively [10], being generally higher in those with overt bleeding. As far 
as DAE is concerned,  although the majority of published studies were performed with DBE 
and significant differences  among DAE devices have been reported (i.e. depth  of SB 
intubation, rate of complete enteroscopy), clinical outcomes (namely DY) seem to be 
consistently similar across studies, regardless of the device used [42-46]. When prospectively 
comparing PE and DAE, the overall DY is significantly higher for DAE [47]. Conversely, when 
lesions located in the proximal SB are considered, the DY appears to be comparable between 
the two techniques [48-50]. Nevertheless, sedation, examination time and X-ray exposure are 
lower with PE. Therefore, PE could represent a reliable diagnostic tool when a lesion is known 
to be located in the proximal SB.   When comparing CTE with DBE in OGIB patients, the DY of 
DBE is significantly higher [51-53]. The DY of CTE increases significantly when a SB tumor is 
suspected [33]; in this subset of patients CTE should precede DAE.  The available studies 
evaluating the performance of CTA in patients with OGIB (including both occult- and overt-
OGIB) showed diagnostic performances inferior to DAE [29]. However, when overt-GI 
bleeders are selected, both techniques yielded similar results [54,55]. Adequately powered 
studies, comparing head-to-head DAE with CTA in patients with occult- and overt-OGIB, are 
lacking, as well as studies comparing MRE and DAE.  
Optimal timing of DAE has not yet been clearly defined, however, proximity to the bleeding 
episode seems to confer higher DYs.  For patients with overt-OGIB the DY of DAE significantly 
increases if the procedure is performed early (within 1 month) after clinical presentation 
[56]. 
 
Statement: The ESGE recommends consideration of the performance of emergency VCE in 
patients with ongoing overt OGIB (strong recommendation, moderate quality evidence).  
 10 
In such patients, the ESGE suggests to consider also DAE as a possible first-line test given its 
ability to make a diagnosis and to perform therapy at the same time (weak recommendation, 
low quality evidence). 
 
The prospect of utilizing VCE for severe ongoing overt-OGIB is appealing due to the relative 
safety, ease and feasibility of the procedure in this setting. In addition, it has already been  
established, that early performance of VCE confers superior DY that translates to better 
patient management and outcomes [8,15,16,20,24,57]. Specifically, with regard to urgent VCE, 
only two retrospective studies [58,59] and one RCT [28], comprising less than one hundred 
patients overall, have been reported so far. Based on limited data, emergency VCE, performed 
within 24Ȃ72 h from admission, during severe ongoing overt-OGIB, appears to be an effective 
modality, with a DY up to 70% and a significant impact on patient management.   
Limited data on the role of emergent DAE for the diagnosis and treatment of severe overt-
OGIB is reported. In a small study of 10 patients with ongoing overt-OGIB, emergency DBE 
was performed within 24 hours of clinical presentation and showed a diagnostic and 
therapeutic yield of 90% [54]. In a separate retrospective report of 120 patients with overt 
OGIB, urgent DBE was defined as DBE performed within 72h from the last visible 
gastrointestinal bleeding; in this study the DY in urgent DBE was significantly higher than that 
in non-urgent DBE, 70% (52/74) versus 30% (14/46), p<0,05 [60]. It also appears that DAE 
may be more cost effective than VCE when a high probability of a positive finding and need for 
therapy exists [61]. Thus, in patients with ongoing overt-OGIB, DAE should also be considered 
as first-line endoscopy, given its ability to make a diagnosis and to perform therapy at the 
same time, and especially in centers where it is readily available and expertise in therapeutic 
enteroscopy exists.  The absolute best strategy for the evaluation of these patients remains 
however unanswered and should be clarified with prospective studies.   
 
Statement: The ESGE does not recommend the routine performance of second-look endoscopy  
prior to VCE, however the decision to perform second-look endoscopy before VCE in OGIB and 
IDA should be undertaken on a case by case basis (strong recommendation, low quality 
evidence). 
Although several studies reported a significant rate of lesions detected by VCE in 
stomach/duodenum or colon in patients with OGIB, the limited available data suggest that the 
yield of repeat systematically EGD and/or ileocolonoscopy prior to VCE (i.e. second-look 
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endoscopy) in these patients is low. Selby et al. reported on 92 patients with OGIB and 
showed that at VCE, lesions were found as often in patients who had only one preceding 
endoscopic evaluation as in those who had multiple endoscopic procedures [62].  
Subsequently, from this same group, Gilbert et al. performed repeat endoscopies (EGD + 
ileocolonoscopy) prior to VCE on 50 patients referred for the investigation of OGIB [63]. A 
probable cause of bleeding was found on repeat EGD in only 2/50 (4%) and repeat 
colonoscopy revealed no additional sources of bleeding.  The authors concluded that the yield 
of repeat EGD and colonoscopy immediately prior to VCE (after a negative preliminary 
endoscopic evaluation) is low when these procedures have previously been non-diagnostic. 
They also concluded that this approach was not cost-effective.  Similarly, Vlachogiannakos et 
al. [64] in a retrospective analysis of 317 patients who underwent VCE for OGIB (after 
previous negative EGD and colonoscopy) reported that in 3.5% of cases, the source of 
bleeding was found in the stomach or the cecum. Routine repetition of conventional 
endoscopy before VCE was not a cost-effective approach. To date, there are no time- or 
referral-based criteria for selecting patients where second-look endoscopy before VCE may be 
worthwhile to perform.  At the present time the decision to perform second-look endoscopy 
before VCE in OGIB and IDA (see below) patients should be taken only on a case by case basis. 
 
 
Statement: The ESGE recommends to manage conservatively those patients with OGIB and a 
negative VCE who do not have ongoing bleeding manifested as overt bleeding or continued need 
for blood transfusions since their prognosis is excellent and the risk of re-bleeding low. The ESGE 
recommends further investigation using repeat VCE, DAE or CTE for patients with OGIB and a 
negative VCE who have ongoing bleeding manifested as overt bleeding or continued need for 
blood transfusions (strong recommendation, moderate quality evidence) .    
 
Up to one third of patients undergoing VCE for OGIB will have a negative VCE.  Several studies 
have shown that in most cases of a normal VCE, re-bleeding rates and the need for 
transfusions are low.  Forty-nine patients who underwent VCE for OGIB were followed up for 
a mean of 19 months;  the overall long-term re-bleeding rate was 32.7%. The cumulative re-
bleeding rate was significantly lower in patients with negative VCE (5.6%) than in patients 
with positive VCE (48.4%) [65]. In another study [66], 42 patients with OGIB were followed 
up for a mean of 17 months after VCE. The overall re-bleeding rate was 28%, and there was a 
statistically significant difference in re-bleeding rates between patients with a positive study 
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(42%) and those with a negative study (11%); both in this last study and in another more 
recent [67], anticoagulant use was associated with an increased risk of re-bleeding. 
Although other studies on this topic came to different conclusions [68] several reviews and 
consensus recommendations [69,70] concluded that patients with OGIB and a normal VCE 
should be managed conservatively without further investigation. Such conservative 
management may include a "wait and see" policy, iron supplementation or blood transfusions. 
Nevertheless, in cases of ongoing overt bleeding or continuous need for blood transfusions an 
alternative approach is warranted. In such patients, repeat VCE can yield a positive finding, 
and especially in patients with a drop in Hb of at least 4 g/dL or in those with a change in 
clinical presentation from occult to overt bleeding [71].  Alternatively, DAE [72,73] or CTE 
[30] can be performed after an initial negative VCE, and can yield a positive finding. 
Randomized controlled trials comparing these modalities in the subgroup of patients with a 
non-diagnostic initial capsule study are still needed to clarify the most appropriate 
management. 
 
 
Statement: In patients with positive VCE, the ESGE recommends DAE as a possible therapeutic 
intervention to confirm and treat lesions identified by VCE (strong  recommendation, high 
quality evidence) .      
 
Teshima et al. [10] found that the pooled DY of DBE performed after a previously positive VCE 
was 75.0% (95% CI: 60.1Ȃ90)  and the odds ratio for the yield of DBE performed after a 
previously positive VCE, compared with that of DBE performed in all patients, was 1.79 (95% 
CI: 1.09Ȃ2.96; p = 0.02). In that same study,  a  subgroup analysis revealed that the pooled DY 
of DBE performed after a previously negative VCE was 27.5% (95% CI: 16.7Ȃ37.8). 
Although studies have assessed the DY of VCE, PE, and DAE in OGIB, the exact significance of 
lesions identified and their impact on clinical outcome has not consistently been evaluated for 
the aforementioned modalities. When we consider outcome in clinical practice, the emphasis 
should be on meaningful results. In the case of OGIB, a positive patient outcome should either 
be cessation of bleeding or resolution of anemia.  In addition, other important clinical 
outcomes to be evaluated may include mortality, hemoglobin levels as well as reduction in 
endoscopic procedures, hospitalizations, and blood transfusions.  Several studies  
demonstrate change in patient management and improved outcomes following VCE [8,16,17] 
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and DAE [56,74-78]. However, prospective comparative trials have not consistently 
confirmed these results [23,27,28].  
 
 
Iron-deficiency anemia 
  
Statement: In patients with IDA, the ESGE recommends that prior to VCE, all the following are 
performed: a complete medical history (including medication use, co-morbidities, and 
gynecological history in premenopausal females), esophagogastroduodenoscopy with duodenal 
and gastric biopsies, and ileocolonoscopy (strong recommendation, low quality evidence).  
 
IDA occurs in 2-5% of adult men and post-menopausal women in developed countries and is a 
common reason for referral to gastroenterologists [79]. According to the most recently 
published practice guidelines, upper and lower gastrointestinal endoscopy are the 
cornerstone for the investigation of IDA (particularly in postmenopausal females and all male 
patients). Bidirectional endoscopy identifies the cause of IDA in 70-80% of patients.  When 
negative, the SB is often targeted for further investigation [79]. 
Although there are no data comparing the effect of different selection criteria on diagnostic 
performance of VCE, the studies applying strict criteria tend to have a higher DY [80-82]. 
Therefore, it is advisable that in patients with IDA referred for SB evaluation, a complete 
work-up should be performed including: bidirectional endoscopy (with ileoscopy whenever 
possible); exclusion of celiac disease (through serology and/or histopathology); complete past 
medical history (paying particular attention to medications and comorbidities); 
gynaecological evaluation (for pre-menopausal women) and haematological evaluation.  
In IDA patients, some authors [83-86] reported an increased incidence, higher than that 
reported in OGIB studies, of lesions detected by VCE within the reach of conventional 
endoscopy; they also reported that after positive VCE, up to 30% of patients with lesions 
identified by VCE have been managed by repeating EGD or colonoscopy.  Unfortunately, 
studies evaluating the cost-effectiveness of a systematic second-look endoscopy before SB 
exploration in IDA patients are lacking. Therefore, at the present time, the decision to perform 
a second-look endoscopy before SB  exploration should be taken on a case by case basis.    
 
Statement: The ESGE can not advise regarding the optimal timing of small bowel evaluation in  
patients with IDA since there are no data on this issue. Nevertheless, the ESGE recommends, in 
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the setting of IDA, an adequate empiric trial of iron supplementation before small bowel  
evaluation  (strong recommendation, low quality evidence). 
 
Although published guidelines recommend an empiric trial of iron supplementation [79] 
before referring patients for SB evaluation, studies focused on IDA do not provide any details 
about that policy in their patients. Whether the systematic application of guidelines can 
impact the referral rate or DY of VCE is therefore unknown. Since we do not have these data, 
at the present time, after a complete diagnostic work-up, it seems reasonable, taking into 
account the chronic nature of IDA and the length of an empiric trial of iron supplementation 
(1-3 months), to institute this before SB evaluation.  
 
 
Statement: In patients with IDA, the ESGE recommends VCE prior to other diagnostic 
modalities, when upper and lower GI endoscopies are inconclusive and small bowel evaluation is 
indicated (strong recommendation, moderate quality evidence).   
 
In a  systematic review, Koulaouzidis et al. [87] reported that, pooling data  from four studies 
focused on IDA  [80-82,88], the DY of VCE was 66% (95% CI: 61.0%-72.3%), which is 
comparable to that reported in other studies on the same topic [9,83,86]. Nevertheless, other 
recent studies [17, 85, 89-91] reported a lower DY, ranging between 25% and 48%. Pooling 
together all studies focused on IDA [80-83,85,86,88-90] the cumulative DY of VCE in IDA 
patients is 53% (95%CI: 41%-65%). There are no studies specifically designed to evaluate the 
DY of PE and DAE in IDA patients. Nevertheless, several studies focused on OGIB patients had 
IDA as part of their inclusion criteria. Thus the DY of PE/DAE in IDA patients should be similar 
to that reported in occult-OGIB patients.  In those studies, the DY of PE varies widely (range 
30-70%; mean approximately 40%) [39,92-96] whereas the DY of DAE appears comparable 
to that of VCE. In a prospective randomized trial, comparing VCE with PE, De Leusse et al. [23] 
found that VCE has a higher DY (50% vs 24%; p<0.05). Although this study was to evaluate 
OGIB patients (half of those referred for SB exploration was for IDA), they reported that the 
yield of the diagnostic procedures was not significantly influenced by the nature of the OGIB, 
therefore we can assume that VCE is superior to PE even when only IDA patients are 
concerned. Retrospective observational studies [91,93,97,98] reporting the DY of PE in IDA, 
which is about 30-60%, appear to support this hypothesis. The success of VCE over 
radiological techniques in IDA patients is mostly related to the nature of findings that, in 50-
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60% of cases, are small, flat vascular lesions [99]. There are no head-to-head studies 
comparing DAE and VCE in IDA patients.  Studies reporting the DY of DAE, when used as a 
primary diagnostic tool in IDA, are scarce and include only a small number of patients [100]. 
Once again, looking at DY of DAE  in OGIB patients only (particularly those with obscure-
occult bleeding), the DY of DAE appears to be comparable [10,13], especially when a complete 
enteroscopy is achieved [9] with that of VCE. Similar DYs  might be reasonably expected in 
IDA patients, also. In the setting of IDA there are two prospective studies comparing head-to-
head VCE and radiological examination. Once again, this comparison is based on DY rather 
than accuracy. VCE has been found to be significantly superior to SB enteroclysis (DY: 56.9% 
vs 11.8%, p<0.001) [88] and to CTE (DY: 77.8% vs 22.2%, p<0.01) [81]. There are no studies 
comparing MRE and VCE in IDA patients. 
With regard to factors potentially associated with a positive diagnosis in IDA patients, a 
favourable association between increased VCE DY and age and severity of anaemia has been 
found [80,89,90]; nevertheless, because of the incidence of relevant findings in young 
patients, age alone cannot be recommended as a reliable criterion for patient selection 
[90,101]. A potential positive association between VCE DY and concomitant anticoagulation 
therapy as well as the presence of comorbidities has been suggested  and needs to be verified 
by further studies [80,89,90,102]. There are no data about factors affecting the DY of DAE as 
the primary diagnostic tool in IDA patients.  
At the present time, there are few studies evaluating the long-term outcome of IDA patients 
undergoing SB evaluation. In addition, the studies that do exist, are retrospective and  
heterogeneous in terms of patient characteristics, follow up length/modalities, and work-up 
performed after the SB examinations. Two studies [83,89], evaluating the impact of VCE in 
IDA patients, reported that overall VCE results led to changes in management, regardless of 
the result of VCE, in 44-60% of patients. This is more evident when the analysis is restricted 
to patients with positive VCE; taking into account both specific therapeutic interventions and 
iron supplementation, change in management occurs in the large majority (up to 100%).  
When specific interventions only (i.e. specific medical therapy - such as steroids, lanreotide, 
thalidomide, gluten free diet- or surgical/endoscopic therapy) are included, changes in 
management are observed in 30-50% of patients with positive VCE. Some studies [83,86,88] 
reported that the rate of resolution of anaemia at the end of follow-up is high (range 57-86%), 
but yielded conflicting results when comparing patients with positive and negative VCE. If 
Apostolopoulos et al. [88] reported a significant difference in the rate of anaemia resolution 
between patients with positive and negative VCE (100% vs 68%; p<0,05), both Sheibani et al. 
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[86] and Holleran et al.  [83]   did not disclose any difference between these two groups. There 
are no studies evaluating the clinical outcome of other diagnostic tools for SB evaluation, as 
primary diagnostic method in IDA patients.  
As far as safety concerns in IDA patients, VCE showed an excellent safety profile (similar to 
that observed in OGIB; capsule retention range 0-4% [81]), whereas there are no specific data 
about DAE safety in IDA patients. Nevertheless it can be expected, a DAE complication rate 
comparable with that observed in OGIB. As far as costs, there are no data about cost-
effectiveness of different diagnostic approaches for the evaluation of the SB in IDA patients. 
This is the main target for further studies taking into account not only efficacy but also local 
costs and reimbursement policies, which differ widely among countries and health care 
systems. 
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Statement: The ESGE recommends ileocolonoscopy as the first endoscopic examination to 
investigate  patients with suspected CD  (strong recommendation, high quality evidence). In 
patients with suspected CD and negative ileocolonoscopy, the ESGE recommends VCE as the 
initial diagnostic modality to investigate the small bowel, in absence of obstructive symptoms or 
known stenosis (strong recommendation, moderate quality evidence). The ESGE does not 
recommend  routine small bowel  imaging or  the  use  of the PillCam patency capsule 
prior to VCE in these patients (strong recommendation, low quality evidence).  In the presence of 
obstructive symptoms or known stenosis,  the ESGE recommends that dedicated SB cross-
sectional imaging  modalities such as MRE or CTE should be used first (strong 
recommendation, low quality evidence). 
 
Up to 66% of patients with CD have SB involvement at diagnosis [103]and in approximately 
90% of patients with SB CD, the disease involves the terminal ileum [104]. Thus, 
ileocolonoscopy is considered to be the first line investigation for CD and is sufficient to 
establish the diagnosis in the vast majority of patients [103]. However, skip lesions of the 
terminal ileum may result in false negative results at ileocolonoscopy [105] and VCE should 
therefore be considered when retrograde ileoscopy is not achieved or when lesions in the 
proximal SB need to be excluded. VCE has been shown to have a consistently high sensitivity 
and high negative predictive value which ranges from 96% to 100% [106-110]. However, the 
lack of a gold standard for the diagnosis of CD hinders precise definition of VCE accuracy for ǮǯǮǯ
in the appropriate clinical context. Furthermore, the mucosal inflammatory changes which are 
found in active SB CD, are not specific to this disease and this has fuelled debate about where 
VCE should fit within the diagnostic algorithm for CD [111,112].  The high DY of VCE versus 
other imaging modalities may therefore not directly translate into a higher diagnostic 
accuracy since lesions detected by VCE may also be induced by other aetiologies [113] such as  
non-steroidal anti-inflammatory drugs (NSAIDs) in particular [114-118]. Moreover, VCE may 
detect minor mucosal breaks and erosions in up to one fifth of healthy individuals [107,119]. 
Nonetheless, VCE has been shown to compare favourably with SB cross-sectional imaging for 
the detection of mucosal lesions consistent with CD [113,120].  
In a meta-analysis conducted by Dionisio et al. [120] VCE was found to be superior to 
SBFT/SB enteroclysis and CTE, with a significant incremental yield (IY) in patients with 
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suspected CD (VCE vs. SBFT/SB enteroclysis: 52% vs. 16% (IY=32%, p<0.0001, 95% CI:16-
48%), VCE vs. CTE: 68% vs. 21% (IY=47%, p<0.00001, 95% CI:31-63%). A recent prospective 
study confirmed that VCE was better than SBFT and equivalent to ileocolonoscopy in 
detecting SB inflammation in patients with suspected CD; this study also suggested that VCE 
can establish the diagnosis of CD in patients with proximal SB inflammation, when 
ileocolonoscopy is negative [121]. Some recent studies have shown that VCE may be superior 
to MRE, particularly for the detection of early disease and proximal SB lesions [122-124]. 
Although MRE and CTE have been shown to have a similar accuracy for the detection of 
inflammation in CD [125-129]. Ǯǡ
factor of increasing concern in the medical community (136) and awareness amongst patients 
(137), but is limited by  higher cost, longer examination time and slightly inferior spatial 
resolution [125]. In a previous prospective, blinded randomised controlled trial by Solem et 
al. [130] which compared VCE, CTE, SBFT and ileocolonoscopy in patients with known or   ȋ        Ǯ ǯȌǡ 
sensitivity of VCE and CTE was similar (83% for VCE, 67% for CTE and ileocolonoscopy, and 
50% for SBFT) but the specificity of VCE was lower (53%) than that of all other tests (100%, p 
< 0.05). The results of this key study highlight the importance of interpreting VCE findings 
within an appropriate and well set clinical context.  
The risk of capsule retention in patients with suspected CD without obstructive symptoms or 
known stenosis and no history of SB resection is low (~ 1.6%)  and similar to that of patients 
who are being investigated for OGIB [11,131-134]. In patients with suspected CD and a 
negative ileocolonoscopy, SB stricturing disease is infrequent and in the absence of suspicious 
clinical symptoms, routine SB imaging or  use of the PillCam® patency capsule   prior to VCE is 
not essential. A careful clinical history may be the most useful way to determine the risk of 
capsule retention in this setting[132,135]. If patients with suspected CD present with 
obstructive symptoms or suspected/known stenosis, dedicated SB cross-sectional imaging in 
the form of CTE or MRE (which may also provide additional evaluation of mural and extra-
mural pathology) should be the method of choice. VCE may still be used in this setting if 
functional patency of the SB is confimed with the use of the PillCam®  patency capsule [136-
138]. 
 
 
Statement: In the setting of suspected CD, the ESGE recommends  careful patient selection 
(using the clinical history and serological/faecal inflammatory markers) prior to VCE, in order 
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to improve VCE diagnostic accuracy for lesions consistent with active small bowel CD (strong 
recommendation, low quality evidence).  The ESGE recommends discontinuation of NSAIDs for 
at least 1 month before VCE since these drugs may induce small bowel mucosal lesions 
indistinguishable from those caused by CD  (strong recommendation, low quality evidence). 
 
Careful patient selection remains critical to increasing the specificity and  PPV of VCE findings. 
At present, no specific index for the diagnosis of CD exists and although the presence of 
clinical symptoms remain an important trigger of the diagnostic process, abdominal pain or 
chronic diarrhoea alone rarely result in the detection of clinically significant SB lesions at VCE 
[139,140]. Some more objective predictive clinical markers of SB CD include the presence of 
weight loss [141], perianal disease [142] raised inflammatory markers [143-146] and faecal 
calprotectin (FC) levels [147-149]. The International Conference on Capsule Endoscopy 
(ICCE) [69] recommended that patients with suspected CD may be appropriate candidates for 
VCE if they present with typical symptoms  in addition to either extra-intestinal 
manifestations of CD, raised serological/haematological inflammatory markers  and/or iron 
deficiency, and/or abnormal SB imaging (e.g. SBFT and/or CTE/MRE). 
FC has recently been shown to be a sensitive marker of intestinal inflammation  [150] and has 
the potential to be used as a cost-effective measure for the selection of patients with 
suspected or known CD being considered for VCE [147-149,151,152].   
NSAID use may be complicated by a drug-induced enteropathy with SB mucosal erosion and 
ulceration which may lead to the formation of short, diaphragm-like strictures [153,154].   
Several VCE studies have shown that NSAIDs (both non-selective and selective Cox-2 
inhibitors)  use may be associated with a high incidence of SB erosion and ulceration (of the 
order of 55% to 75%) [115-118,155-157]; chronic low dose aspirin has also been shown to be 
associated with the presence of similar SB lesions [158,159]. Since the endoscopic 
appearances of SB lesions induced by NSAIDs are endoscopically indistinguishable from 
lesions caused by other aetiologies such as CD, their presence may be confounding and 
potentially lead to misdiagnosis. In view of this, NSAIDs should be stopped before VCE, 
particularly if the patient is being investigated for the presence of active SB CD. Although 
recommendations in the current literature are heterogeneous, arbitrarily stopping these 
agents for at least 1 month before VCE appears to be an acceptably prudent strategy [117]. 
 
Statement: In patients with established CD based on ileocolonoscopy findings, the ESGE 
recommends dedicated cross-sectional imaging  for small bowel evaluation since this has the 
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potential to assess extent and location of any CD lesions, to identify  strictures and assess for 
extra-luminal disease (strong recommendation, low quality evidence). In patients with 
unremarkable or non-diagnostic cross-sectional imaging of the small bowel, the ESGE 
recommends VCE as a subsequent investigation, if deemed to influence patient management 
(strong recommendation, low quality evidence).  When VCE is indicated, the ESGE recommends 
PillCam patency capsule use to confirm functional patency of the small bowel (strong 
recommendation, low quality evidence). 
 
In patients with known CD, irrespective of the findings at ileocolonoscopy, further 
investigation is recommended to assess the extent and location of any CD lesions in the more 
proximal SB, since any positive findings may have prognostic and therapeutic implications 
[103]. Dedicated SB cross-sectional imaging with CTE or MRE generally takes precedence 
over VCE for the evaluation of the SB in patients with established CD, since these modalities 
may also identify strictures and have the ability to assess the transmural and extra-luminal 
nature of the disease and its anatomical distribution [111].  
Dionisio et al. [120] showed that VCE was superior to SBFT/SB enteroclysis and CTE in the 
evaluation of patients with known CD, with a significant higher DY (VCE vs. SBFT/SB 
enteroclysis: 71% vs. 36 %, IY  = 38 % , p < 0.00001, 95 % CI: 22% Ȃ 54 %; VCE vs. CTE: 71% 
vs. 39 %, IY  = 32 % , p = < 0.0001, 95 % CI: 16% Ȃ 47 % ). Conversely, the DY of VCE was 
found to be inferior to that of MRE: 70% vs.  ? ? ?ǡ ? ? ? ?ǡ ? ?Ǥ ? ?ǡ ? ? ?ǣ ? ? ? ? ? ?
%.  Nonetheless, VCE has been shown to improve the detection of lesions in the proximal SB 
when compared to both CTE and MRE [122,160] and may detect proximal SB lesions in up to 
50% of patients with previously diagnosed ileal CD [161]. Despite the suggestion from a 
recent study that CTE or MRE may be sufficient for the investigation of most patients with 
known SB CD [162], VCE may still be of value if a CD flare-up is still suspected despite 
negative SB cross-sectional imaging. In this context, VCE may be used as a further 
investigation if the presence of SB mucosal lesions may influence patient management. 
Although prospective controlled trial data are lacking, a few retrospective studies have 
highlighted the potential impact of VCE on the management of patients with established CD 
[163-170].  
The risk of capsule retention is increased and can be of the order of 13% in patients with 
known CD [11,132-134,171,172]. Although findings of SB stenosis at CTE or MRE may 
preclude subsequent VCE in 27 to 40% of patients with known CD [125], not all strictures 
actually result in significant mechanical obstruction and the use of the PillCam® patency 
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capsule may help to identify patients who are at increased risk of capsule retention [136]. One 
retrospective study compared the performance of the patency capsule and radiological 
examinations to detect clinically significant SB strictures [137]. In this study, both methods 
were equivalent, suggesting that if cross sectional imaging show no stricture or the patency 
capsule is excreted intact, the patient will most likely pass the actual capsule safely.  
 
Statement: The ESGE recommends an initial conservative treatment in case of a retained 
capsule. The ESGE recommends DAE if medical therapy has not been able to promote 
spontaneous passage  (strong recommendation, low quality evidence). 
 
Cases of capsule retention can often be managed conservatively   with anti-inflammatory 
agents and/or immunomodulators [173], resulting in spontaneous passage of the capsule 
[174]. If the capsule does not pass spontaneously after a trial of medical therapy, it may be 
retrieved by DAE [175,176]. If attempts at endoscopic capsule retrieval are unsuccessful and 
the patient is clinically well and without obstructive symptoms, an observant, conservative 
approach may be appropriate in this setting and only a minority of patients will need to 
undergo surgery to retrieve a retained capsule. In a large retrospective study of 2300 patients 
[177], including 301 with known CD, of whom 196 (65.1%) had definite SB involvement; 
capsule retention occurred in only 5 patients (1.66%). In 3 of these patients, the capsule 
passed spontaneously after a course of glucocorticoid therapy, while in the other 2, surgery 
was required for capsule retrieval.  
 
 
Statement: The ESGE suggests the use of activity scores (such as the Lewis score and the 
  ǯ   Ȍ     follow up of 
patients for longitudinal assessment of the course small bowel CD and its response to medical 
therapy (using mucosal healing as an endpoint) (weak recommendation, low quality evidence). 
 
Efforts are being made to introduce standardised quantitative scoring systems to describe the 
type, location and severity of SB lesions [178]Ǥ ? ?
Mow et al. [108] although widely used, does not assess the distribution or the severity of 
inflammatory activity, does not consider other inflammatory features such as oedema or 
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stenosis, and has a modest positive predictive value of 50-69% for the diagnosis of CD 
[107,163,179]Ǥ    ǯ    ȋȌ 
evaluates three parameters of SB pathology in CD: inflammation, extent of disease and 
presence of strictures, both for the proximal and distal segments of the SB, based on SB transit 
time of the capsule. This score has been recently validated in a multi-centre prospective study 
[180,181]. The Lewis score [182,183] is a cumulative scoring system which is based on the 
presence and distribution of villous oedema, ulceration and stenosis.  It should be emphasised 
that although these scoring systems can quantitatively describe the type, distribution and 
severity of mucosal lesions, they cannot be used as a diagnostic tool per se [184]. In view of 
the non-specific nature of SB inflammatory lesions, the results of these scoring systems must 
be interpreted in the appropriate clinical context, in corroboration with other findings; it 
should be borne in mind that a diagnosis of active SB CD cannot be based upon the 
appearances seen at VCE alone.  
Mucosal healing is recognised as an increasingly important endpoint for assessment of 
therapeutic efficacy in patients with inflammatory bowel disease (IBD) and recent clinical 
trials have begun to evaluate the potential role of VCE for its assessment in the SB [185-187] 
using quantitative scores such as the Lewis score [183] or CECDAI [181] for this purpose in 
research trials and clinical practice, analogous to the application of the CDEIS  or SES-CD to 
ileocolonoscopy [188]. 
The potential role of VCE in the assessment of patients with IBD unclassified (IBDU) has also 
been investigated. Although current data is scant, there is a suggestion that the findings at 
VCE may help to establish a definite diagnosis and SB lesions compatible with CD may be seen 
in up 17% -70% of patients with this condition [163,189-191]. However, it must be borne in 
mind that a negative VCE only rules out current disease activity and cannot definitely exclude 
a future diagnosis of CD in these patients [192,193].  
In the natural history of CD, intestinal resection is unavoidable in a significant proportion of 
patients. A majority of patients develop disease recurrence at or above the  anastomosis and 
endoscopic recurrence precedes the development  of clinical symptoms. Although VCE has 
been shown to detect superficial proximal SB lesions (undiagnosed by other modalities)  in 
patients with CD early after surgery,  the clinical significance of these findings and how they 
may impact on patient management remains a matter of debate [194]. VCE currently should 
not replace ileocolonoscopy in the routine management of patients after surgery; it should be 
considered in the assessment of postoperative recurrence when ileocolonoscopy is 
unsuccessful or contraindicated [195-198]. 
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Statement: The ESGE recommends DAE with small bowel biopsy in patients with non-
contributory ileocolonoscopy  and suspicion of CD on small-bowel cross-sectional imaging 
modalities or VCE. DAE with small bowel biopsy is more likely to provide definitive evidence of 
CD than cross sectional imaging tests, although these latters offer a useful less invasive 
alternative which better defines transmural complication (strong recommendation, high quality 
evidence).   
 
Although there is no gold standard for the diagnosis of CD and a corroboration of clinical and 
investigation findings are required [103], its presence can be supported by the findings at 
ileocolonoscopy in the majority of patients with suspected CD [113]. Dedicated SB cross-
sectional imaging  (CTE or MRE) should be considered if symptoms raise suspicion for the 
presence of stricturing or perforating disease and is complementary to VCE which in turn is 
more sensitive in detecting mucosal inflammation [110,120,199].  PE may provide direct 
endoscopic assessment and biopsies for histopathology especially in patients whose prior 
radiological or VCE findings suggest a lesion within the proximal SB [93,200,201]. Lesions 
which lie deeper in the SB, beyond the reach of ileocolonoscopy and PE, may be accessed by 
DAE which should be considered if histological assessment is needed to confirm a diagnosis of 
CD or exclude other conditions which mimic the appearance of CD, such as infections or 
malignancy [202-207]. 
In the setting of suspected SB CD, the DY of DAE ranges between 22% and 70% [202,203,208], 
being higher if the indication for DAE is based on previous SB investigations (which may 
identify suspected lesions and guide the route of insertion) [203]. Two meta-analyses [13,14] 
showed that VCE and DBE  have similar DYs. The authors concluded that in view of its non-
invasive nature, VCE should be considered first.    
In the setting of patients with established CD, the presence of SB strictures may limit  safe use 
of VCE and as a result, DAE may be considered earlier in the evaluation of such patients [209]. 
DAE may allow complete SB examination and has a higher yield in patients where a high 
clinical index of suspicion for active CD persists. In such a setting, when compared to 
radiological test, DAE seems to be more accurate than SB barium contrast studies [210] and 
MRE [211,212]. As for other settings, positive findings at DAE were more likely if  these were 
guided by the findings of prior diagnostic imaging;  which may also identify  optimal route for 
insertion [26,203,213]. DAE, however, is technically challenging, may require a bidirectional 
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approach, deep sedation or general anaesthesia and has a major complication rate of around 
0.72% (which may be higher in patients with CD) [214] and therefore should only be 
performed if it alters therapeutic strategy. In a small prospective trial, positive findings at 
DAE led to a step-up of medical therapy in 26 of 35 patients (74%), leading to clinical 
remission in 23 (88%) [209]. 
  
Statement: The ESGE recommends DAE if small bowel endotherapy (including dilation of CD 
small bowel strictures, retrieval of foreign bodies and treatment of small bowel bleeding) is 
indicated (strong recommendation, low quality evidence). 
  
Reported indications for DAE in the setting of known or suspected CD include diagnosis and 
therapeutic endoscopy in patients with bleeding [203,210], dilatation of strictures (EBD) in 
symptomatic patients and retrieval of retained capsules [203,215]. Technical success in 
dilating strictures which are accessible, less than 5cm in length without severe inflammatory 
activity is reported in between 60 and 80% of patients and repeat EBD may be undertaken 
[216-218], but long-term outcomes are less well known. Perforation rates following EBD of 
CD related strictures at DAE may be as high as 9% [216,219-222].  
 
 
Statement:  
The ESGE recognises VCE/DAE and MRE/CTE as complementary strategies (weak  
recommendation, low quality evidence). Cost-effectiveness data regarding optimal investigation 
strategies for diagnosis of SB CD are lacking. 
 
Cost-effectiveness analyses are intended to support resource-allocation decisions and are 
therefore dependent on local/regional socio-economic perspectives [223]. Diagnostic 
techniques may affect patient outcomes indirectly by their influence on subsequent 
management strategies, implying that benefits from a specific diagnostic test depends on 
performance characteristics (e.g. sensitivity and specificity) as well as other factors, such as 
prevalence of the disease and effectiveness of available treatments [224]. In Europe alone CD 
directly results in a healthcare expenditure of between 4.6 to 5.6 billion Euros per year. In 
addition to this the indirect costs are estimated to be twice as high as the direct costs [225] 
and any delay in establishing the diagnosis may augment this burden further [226]. Mitigation 
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of this by cost-effective diagnostic and therapeutic strategies is therefore paramount. The use 
of high pre-test probability indicators in suspected SB CD (such as the application of the ICCE 
criteria [69] +/- appropriate use of faecal inflammatory markers [147-149,227] may improve 
allocation of limited resources and reduce the need  for more invasive and expensive 
diagnostic investigations in patients with a low pre-test probability. In patients with strongly 
suspected CD, ileocolonoscopy is the diagnostic method of choice to detect colonic CD and/or 
disease activity in the terminal ileum. In order to establish disease extent at first presentation, 
further SB imaging should be included in the diagnostic work-up, however the preferred, 
most cost-effective method for this remains unknown [228]. In about 10% of patients, CD only 
affects the SB proximal to the terminal ileum and disease activity in these patients may not be 
detected by ileocolonoscopy. The most cost effective diagnostic algorithm vis-à-vis SB 
endoscopy vs. dedicated cross-sectional imaging in patients with a negative ileocolonoscopy is 
still under debate. Cost-effectiveness analysis of performing VCE immediately after 
ileocolonoscopy or only after dedicated SB cross-sectional imaging in patients with suspected 
CD has produced conflicting results [229]. Although meta-analysis suggest a higher sensitivity 
and optimal negative predictive value for endoscopic methods as compared with radiology, 
transmural and extramural lesions are only detected by dedicated SB cross-sectional imaging 
[120] and these two types of  technology are therefore best considered complementary [230]. 
Cost-effectiveness comparisons of currently available SB radiological investigations have also 
yielded conflicting results. Sensitivity analysis in one study suggested that in patients with a 
high prevalence of complications, MRE becomes as cost-effective as SBFT/SB enteroclysis 
which although cheaper, is less accurate and may miss extramural disease while exposing 
patients to ionising radiation [231]. A comparison of MRE and CTE showed that although MRE 
has the advantage of being radiation free and allows dynamic evaluations of SB peristalsis, it 
is a more expensive and longer examination with slightly inferior spatial resolution. In   ȋ ? ? ? -of-age), MRE is likely to reach cost-effectiveness (when 
compared to CTE), however low-dose CTE may become an alternative cost-effective choice in 
the future [232]. Although cost-effectiveness comparisons of algorithms involving VCE and 
DAE in the setting of SB bleeding have shown that a capsule-directed DAE appears to be the 
most cost-effective strategy [61,233], similar data for VCE vs. DAE in the workup of CD are 
lacking. DAE also offers the potential to apply endotherapy (such as EBD of strictures) in 
patients with SB CD and this may considered as a beneficial and effective alternative to 
surgery in selected patients [216,221]; however, cost-effectiveness or comparative studies of 
endoscopic vs. surgical treatment of SB strictures are not available. 
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Small bowel tumours    
 
Statement: The ESGE recommends early application of VCE for the search of a small bowel 
tumour when OGIB and IDA are not explained otherwise   (strong recommendation, moderate 
quality evidence). 
 
Most of SB tumours (SBT) are detected during work-up of OGIB or IDA, but represent only 
about 3.5-5% of these patients [87], making this symptom a weak predictor. The clinical 
manifestations of SBT, unfortunately, tend to be very unspecific; which can delay the 
diagnosis, especially in the early stages.  Associated with a higher risk of SBT are non-
Hodgkin´s lymphomas as follicular lymphoma, hepatic metastasis of previously undiagnosed 
primary neuroendocrine tumor [234-236], and malignant melanoma in stage IV or in stage III 
with positive fecal occult blood test [237]. Complicated celiac disease with anemia, persistent 
complaints in spite of gluten-free diet, refractory celiac disease may be associated with T-cell 
lymphoma or adenocarcinoma [238,239] and might represent an indication for VCE.  
Data on SB endoscopy in SBT are often retrieved as small part from larger mixed series, the 
small percentage of SBT compared to other findings in OGIB makes prospective trials almost 
impossible. A meta-analysis showed that VCE has a significantly higher DY compared to PE in 
patients with OGIB [12]: for the small number of included tumors, VCE only showed a non-
significant trend towards higher DY than PE. In a highly selected group of 30/112 patients 
with SBT detected by VCE, PE had a DY of 70% [240]. Thus,, PE could represent a reliable tool 
for further work-up of SBT clearly localized to the proximal jejunum. In OGIB patients, VCE DY 
is similar to that of DBE [10,13] and of IOE [6]. Translating these results also to the small 
subgroups of patients with SBT included in these studies, VCE appears to be sufficiently 
accurate in detecting SBT. Of note, compared to DBE, concordance of findings was less good in 
patients with SBT than in patients with inflammatory and vascular lesions [241]. Factors 
associated with diagnosis of SBT by DBE were suspected tumour at radiology or VCE, 
evaluation or therapy of disease as lymphoma, but not presence of stenotic symptoms, sex 
and age. Indication of OGIB was significantly lower in patients with SBT diagnosed at DBE 
[242]. Thus, DBE is rather applied in a highly selected group, while VCE may serve as a filter 
for patients with SBT in the large group with OGIB. Positive findings at VCE, including tumors, 
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can direct the insertion route for DAE in case of [25,26], and previous VCE increases the DY of 
subsequent DAE [10].  
The risk of false negative results in VCE should be always considered, being more frequent in 
large SBT and polyps, in duodenum and proximal jejunum, and in submucosal masses with 
missing mucosal component like neuroendocrine tumors or gastrointestinal stromal tumors 
(GIST) [73, 235, 243-246]. VCE seems to be superior to SB barium radiography [12,240,247]. 
Data concerning CTE and MRE are sparse and contradictory. MRE was demonstrated having 
high sensitivity (86%) and specificity (98%) for SBT [248]. In a retrospective analysis of 77 
patients, specificity of MRE was higher than that of VCE (0.97 vs. 0.84, p = 0.047), whereas 
sensitivity was similar (0.79 vs. 0.74, p = 0.591) [249]. In a prospective blinded comparison, 
the overall DY for VCE and multiphase CTE was similar in 58 patients with OGIB: 28 (48%) for 
CTE and 25 (43%) for VCE. However, CTE diagnosed 9/9 SBT, while VCE found only 3 (33%) 
[33]. On the other hand, VCE was superior to CTE in detecting SBT in patients with Lynch 
syndrome by detecting one carcinoma and two adenomas while CTE only raised suspicion of 
one carcinoma [250]. 
SBT diagnosis by VCE can be challenging. A retrospective analysis demonstrated that a 
proposed tumor score composed of bleeding, mucosal disruption, an irregular surface, color, 
and white villi was helpful to identify SB mass lesions [251]. A score (SPICE for smooth 
protruding lesions (with the criteria: unsharp edge with the surrounding mucosa, diameter 
larger than height, non-visible lumen in the frames  in which it appears, and an image lasting 
less than 10 minutes) had a sensitivity of 83 % and a specificity of 89% in a small prospective 
study. However, 2 false positive and 1 false negative diagnosis of SBT were still encountered 
[252]. Further larger prospective studies are needed to validate such scoring systems.  
 
Statement: In the setting of suspicion of a small bowel tumour, the ESGE does not recommend 
specific investigations before VCE in patients without evidence for stenosis or previous small-
bowel resection (strong recommendation, low quality evidence).  The ESGE recommends to 
consider DAE over VCE if there is already a suspicion of SBT at imaging tests (strong 
recommendation, low quality evidence). 
Most patients with SBT detected at VCE had the indication of OGIB or IDA [253]. Considering 
that only a minority of such patients  have a neoplasm [240], that retention rate in SBT is only 
slightly higher than in other bleeding disorders [134,247],  that retention is in general 
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asymptomatic [240], and that most patients with SBT will undergo surgical resection of the 
tumour (with the possibility to retrieve the capsule easily) it does not seem justified to 
perform tests routinely to exclude a stenosis before VCE in bleeding patients without clinical 
evidence for obstruction. Conversely, if there is already a suspicion of SBT at imaging tests, 
DAE should be considered over VCE, in order to avoid capsule retention and to obtain 
histology.  
 
Statement: The ESGE recommends cross-sectional imaging to ascertain operability when a VCE 
finding of SBT with a high diagnostic certainty is identified. In case of uncertain diagnosis of SBT 
at VCE, biopsy sampling by DAE is required (strong recommendation, low quality evidence). 
When a submucosal mass is detected by VCE, the ESGE recommends to confirm the diagnosis by 
DAE (strong recommendation, low quality evidence).  In case of high suspicion of submucosal 
mass at VCE and a negative but incomplete DAE, the ESGE suggests cross-sectional imaging tests 
to confirm the diagnosis (weak recommendation, low quality evidence). 
 
In case of a clear diagnosis of SBT at VCE (ulcerated, bleeding mass lesion, stenosis) surgery 
without previous histology seems justified. Cross sectional imaging techniques should be 
requested to exclude inoperability. Uncertain protruding SB lesions detected by VCE require 
DAE or imaging techniques, since innocent bulges may be confused with submucosal tumours 
(false positive VCE findings). A tattoo placed during DAE may facilitate recognition of small 
mass lesion at subsequent (laparoscopic) surgery [240]. 
 
Most studies on DAE in SBT are related to DBE. Small series on SBE and SE suggesting similar 
results need further confirmation. When compared to VCE, DAE seems to have comparable 
sensitivity. A lower specificity of VCE seems to be related to the high rate of false positive 
(mainly submucosal) masses . In a Chinese series, all 32 tumors detected by VCE and 
confirmed by DBE were further confirmed by surgery [26]. Six further submucosal tumors 
suspected at VCE were considered as false positive findings, as they were not confirmed by 
DBE. DBE was superior to CT scan in diagnosis of SBT, including submucosal masses 
[254,255].  In a series of 12 GIST, the detection rates of DBE, VCE and CT were 92%, 60% and 
67%, respectively. All cases, except for one incomplete study, were identified using DBE. One 
case was not diagnosed as a tumor because of the presence of extramural growth [245]. In a 
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study of 159 patients with SBT, VCE and DBE had significantly higher DYs than contrast 
enhanced computed tomography (CECT), and DBE had significantly higher DYs than VCE, but 
a combination of CECT and VCE had a DY similar to that of DBE [256].  
 
Statement: The ESGE recommends against VCE in the follow up of treated SBT because of lack 
of data (strong recommendation, low quality evidence). 
 
VCE detected lesions similarly as DBE in treated follicular lymphoma. However, as 
identification of residual lymphoma required biopsy, the authors recommend DBE for follow-
up [257]. Only one of 11 patients with VCE diagnosis of malignant SBT who underwent 
surgery had recurrent bleeding due to metastasis of gastric and papillary cancer in familial 
adenomatous polyposis (FAP) [258]. There are no studies to support regular follow-up of 
asymptomatic patients after resection of SBT in the absence of inherited polyposis 
syndromes. 
 
 
Inherited polyposis syndromes  
x Familial adenomatous polyposis 
Statement: The ESGE recommends that surveillance of the proximal small bowel in FAP 
is best performed using conventional forward and side-viewing endoscopes (strong  
recommendation, moderate quality evidence). 
When small bowel investigation is clinically indicated in FAP, the ESGE suggests that VCE 
and/or cross-sectional imaging techniques may be considered for identifying polyps in 
the rest of the small bowel, but the clinical relevance  of such findings  remains to be 
demonstrated  (weak recommendation,  moderate quality evidence) 
 
In FAP, the reference examination for the proximal SB, according to the high cumulative risk 
of severe duodenal polyposis and high relative risk of duodenal cancer is axial and lateral 
viewing endoscopy in the same time [259-262].  Jejunal and ileal polyps can be found in 40-
70% of FAP patients; a  correlation between the severity of duodenal polyposis and the 
presence of more distal SB polyps has also been demonstrated [261,263-265]. It is known that 
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adenomas in the duodenum and the periampullary region are poorly identified with VCE, at 
least with an accuracy that is inferior to that of axial viewing endoscopy [265,266]; exact 
polyp size estimation is another limitation of VCE [267].  
Studies comparing PE to VCE in FAP patients showed conflicting results [264,268], whereas 
systematic comparison of VCE with DAE in these patients is still warranted. VCE 
demonstrated higher sensitivity for polyps than radiological investigations such as SB barium 
studies and MRE [240,264,265,269]. The location of bigger polyps and determination of their 
exact sizes has shown to be more accurate by MRE  than VCE [269]. The  clinical relevance of ǲǳ 	  
hyperplasia, without evidence for advanced adenomas [270] and considering the low 
frequency of jejunal and ileal carcinomas in these patients [271].  
FAP patients present with desmoid tumors in 10 % of cases. Asymptomatic extensive 
mesenteric desmoid tumors represent a risk in this situation. Cases of acute occlusion related 
to VCE retention have been reported including a case of desmoid in a FAP patient [272,273]. 
Exclusion of intraabdominal desmoid tumors by imaging techniques seems reasonable in FAP 
patients if VCE is considered.  
Limited evidence exists concerning the use of DAE in FAP patients [274-277]. If polyps larger 
than 1 cm are identified at VCE or with cross-sectional imaging techniques, DAE is usually 
performed in order to obtain targeted biopsies and accomplish local endoscopic therapy 
[265,278]. Although technically feasible, the value of such an approach in these patients has 
yet to be demonstrated. In FAP patients with reconstruction with a Roux-en-Y anastomosis 
after a Whipple procedure, DAE may be useful for investigation of such anatomically altered 
bowel segments [279].  
 
 
x Peutz-Jeghers syndrome (PJS) 
Statement: The ESGE recommends small bowel surveillance in PJS patients. VCE and/or  
MRE appear adequate methods for this purpose, depending on local availability and 
expertise, or patients´ preference (strong  recommendation, moderate quality evidence).   
 
The initial main purpose of SB surveillance in Peutz-Jeghers syndrome (PJS) patients is to 
reduce the polyp burden and the likelihood of polyp related complications, particularly 
intussusception. With advancing age, this focus may shift to the early detection of SB cancer or 
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precancerous lesions; however, the preventive effect of surveillance on development of such 
neoplasia remains to be proven [280,281]. VCE has a greater sensitivity than SBFT in 
detecting SB polyps [282-284].   When compared to MRE, VCE was superior at detecting small 
polyps. Polyps >1 cm were detected equally with both modalities and location of polyps and 
determination of their exact sizes was more accurate with MRE [269,285,286]. MRE was also 
shown to be less prone to missing large polyps than VCE [285]. A small study reported a 93% 
concordance between MRE and enteroscopy (i.e. DBE, laparoscopic endoscopy or surgery) for 
larger (>15 mm) and more risky polyps [287]. Compared to DAE, VCE has the advantage to 
allow a more complete examinations of the SB in PJS patients, however false-negative results 
may occur with VCE [288,289]. In a retrospective multicenter study, 25 patients underwent 
VCE followed by consecutive DBE when treatment was indicated. Authors found a strong 
agreement for polyp location and  size, but not for number of polyps for which DAE was more 
accurate [290]. The PillCam® patency capsule test may be considered before VCE in PJS 
patients with history of prior SB resection, as it has been shown to be useful in detection of 
relevant stenosis [136,291].   
  
Statement: The ESGE recommends DAE with timely polypectomy when large polyps ( > 
10-15 mm) are discovered by radiological examination or VCE in PJS patients (strong  
recommendation, moderate quality evidence). 
 
 It is now well acknowledged that polyp size is the most important risk factor for SB 
intussusception with intestinal obstruction and that intussusception is generally due to   ?  ? ?   [292-294]. Consequently, large polyps (10-15 mm) or 
symptomatic or rapidly growing polyps should be removed.   DAE is clinically useful for 
diagnosis and relatively safe for therapy of SB polyps in PJS patients, both in adults and in 
children [277,292,295-299].  
A study described 29 diagnostic and therapeutic DBE procedures in 13 patients with PJS, with 
removal of multiple polyps > 1 cm [295] without  complications. However, two other studies,  
report a complication rate of up to 6.8%, including acute pancreatitis (2.7%) [297] and post-
polypectomy syndrome (5%) [296].    
In PJS, completeness of SB investigation by DAE may be jeopardized by previous laparotomies 
[296]. If there is no information on polyp burden an initial VCE/MRE from the age of 8-10 
years [280,281,293,300] may be preferred to select only those patients for DAE with a need 
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for therapy. In case of high polyp burden, incomplete polypectomy during preceding DAE, 
next surveillance may be preferably done by DAE as this is more cost-effective in a setting 
with high percentage of therapy.  Indeed, repeated DBE examinations have been reported to 
reduce SB polyp burden and to prevent polyp-related complications as intussusception [295-
297]. In case a polyp is too large for safe removal with DAE or when a polyp cannot be 
reached with DAE, IOE could be considered for polypectomy or enterotomy.   
 
 
Celiac Disease   
Statement: The ESGE strongly recommends against the use of VCE for suspected celiac disease 
but suggests that VCE could be used in patients unwilling or unable to undergo conventional 
endoscopy (strong recommendation, low quality evidence). 
 
Celiac disease  is a common autoimmune condition characterised by a heightened 
immunological response to ingested gluten, with prevalence rates in the United States and 
European populations estimated to range between 0.2-1% [301,302]. The current gold 
standard diagnostic test for celiac disease is EGD with duodenal biopsies and SB histology 
demonstrating the presence of villous atrophy (VA) (Marsh 3a to 3c) [303]. Corroborative 
evidence used to support the diagnosis of celiac disease comes from positive serological tests 
(tissue transglutaminase (tTG) and endomysial (EMA) antibodies) and a clinical response to a 
gluten-free diet (GFD). Occasionally when diagnostic uncertainty exists, human leucocyte 
antigen (HLA) typing is undertaken which may help to exclude celiac disease, given the high 
negative predictive value of this test. 
There are several potential limitations of EGD as part of this diagnostic pathway.  These 
include its invasive nature and its inability to evaluate SB mucosa beyond the duodenum.   
Changes of celiac disease are well recognised to be patchy [304] and occasionally in some 
patients the SB distal to the reach of a standard gastroscope may be more affected than the 
proximal bowel where biopsies are taken [305-307].     There has been increasing interest in 
the role VCE may have in celiac disease.  With an 8-fold magnification power comparable to a 
dissecting microscope, VCE has the potential to detect VA and other SB complications seen in 
celiac disease.   
In the studies assessing the utility of VCE in diagnosing celiac disease, sensitivity, specificity, 
PPV and NPV of VCE were  70-100%, 64-100%, 96-100% and 71-93%, respectively [305,308-
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311]. A consistent finding in all of these studies is that the PPV and specificity in the presence 
of EMA or significantly elevated tTG for the recognition of endoscopic markers of celiac 
disease is 100%. However, the high pre-test probability of celiac disease in all of these studies 
may again be a potential limitation leading to an overestimation of VCE performance.  
However they accurately reflect real life clinical practice where patients are likely to be 
selected for VCE of the basis of positive serology and suggest that VCE may be an appropriate 
tool for patients who are unable to undergo EGD.     
 
Statement: The ESGE recommends that there is no role for VCE to assess the extent of disease or 
response to a gluten-free diet (strong recommendation, low quality evidence). 
 
One area where VCE may confer an advantage over standard endoscopy is that VCE has the 
potential to image the entire SB.    It would seem intuitive that the more of the bowel that is 
affected the more severe symptoms and the higher the chance of potential complications.  
However this has not been proven mainly because it is difficult to assess the extent of disease.  
In a study of 38 untreated celiac patients and 38 controls [305], the authors were unable to 
show a relationship between either qualitative or quantitative measurements of extent of 
disease and severity of clinical presentation, however a positive EMA was associated with 
more extensive disease.  In the 30 celiac patients who agreed to repeat VCE after GFD, the 
mean time with abnormality reduced from 60 minutes to 12 minutes.  A second more recent 
study of 12 patients with celiac disease who had repeat VCE after 12 months on a GFD has 
also demonstrated this improvement [310].  Although there was no initial correlation 
between extent of disease and clinical severity they did demonstrate a significant reduction in 
the mean time with VA. These two studies have so far failed to demonstrate any relationship 
between extent of SB involvement and clinical severity of disease. As experience with VCE in 
celiac disease  increases however this may become possible.  
 
Statement: The ESGE suggests the use of VCE in equivocal cases of celiac disease (weak 
recommendation, low quality evidence). 
 
Another area where VCE may play a role is in the investigation of equivocal cases of celiac 
disease. The changes of celiac disease can be patchy and a duodenal biopsy in patients with 
positive serology may not demonstrate VA.  Lesser degrees of histology that can be associated 
with celiac disease are non-specific and are seen in a variety of other conditions.  This can 
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leave some patients without a definitive diagnosis. In a study of 8 patients with positive 
serology (EMA or tTG) and a normal duodenal biopsy, VCE did not reveal any endoscopic 
features of celiac disease [310]. Thus the investigators concluded that there was no benefit in 
performing VCE for this sub-group of patients; another similar study came to the same 
conclusions [312]. There is however conflicting evidence. In a further study of 30 patients 
with Marsh 1 or 2 changes, only 6 of whom had positive EMA or tTG, one patient was 
diagnosed with celiac disease  and another with SB CD on the basis of VCE appearances [313]. 
It is clear that further work is required to assess the cost effectiveness of the use of VCE in 
these equivocal cases if the yield is as low as in this final study.  VCE use may be justified 
however, in EMA or tTG positive patients with Marsh 1 or 2 changes or gastrointestinal 
symptoms particularly if they are unwilling to undergo further EGD and repeat biopsies.  
Patients with antibody-negative VA represent another diagnostic challenge since there is a 
wide range of differential diagnoses for VA.  In the study of equivocal cases by Kurien et 
al.[313] they also included a group of patients with antibody-negative VA to see if this 
increased the DY.  Patients were extensively investigated for celiac disease including HLA 
phenotyping, by monitoring response to GFD and in some cases repeat duodenal biopsies.  On 
the basis of VCE appearances and other ancillary tests 7 patients could be diagnosed with 
celiac disease and 2 further patients were diagnosed with SB CD as a cause for VA.  Again this 
is a single small study and further work needs to be done to clarify the role of VCE in 
antibody-negative VA cases. This is particularly important as VCE alone is probably 
insufficient to confirm a diagnosis of celiac disease as endoscopic markers are not specific to 
celiac disease rather they are predictors of mucosal disease [314].   
 
 
Statement: The ESGE recommends initial assessment by VCE followed by DAE in non-responsive 
or refractory celiac disease (strong recommendation, low quality evidence). 
The distribution of serious complications of celiac disease such as refractory celiac disease 
(RCD) and enteropathy associated T-cell lymphomas (EATL) is particularly important  as 
these appear to be more commonly seen in the distal SB [315-319]. Ulcerative jejunitis is 
usually associated with RCD type II and with a high risk of developing EATL.  Early 
identification of RCD type II may allow effective treatment with immunosuppression and 
prevent progression to EATL.  VCE could therefore play a role in the investigation of these 
patients . In two studies of patients with  celiac disease and persisting symptoms, a few 
 35 
serious complications were identified by VCE including cases of EATL, ulcerative jejunitis, 
RCD type I and II, some of which were confirmed by DBE and biopsy [313, 316]. The use of 
VCE to assess the extent and severity of disease in patients with known RCD may also be 
helpful as shown in a recent study of 29 patients with RCD and 9 patients with symptomatic 
celiac disease [239].  Three cases of EATL were identified and 5 cases of ulcerative jejunitis 
requiring specific treatment in the RCD cohort.  The majority of the RCD patients also 
underwent DAE and the authors concluded that 17 patients could have avoided this invasive 
investigation based on VCE findings. Apart from this final study, where there was an unusually 
high proportion of patients with RCD, the apparent DY for complications such as EATL and 
ulcerative jejunitis appears low.  However these diagnoses carry significant rates of morbidity 
and mortality which may be reduced by prompt diagnosis.  The use of capsule followed by 
DAE [320.321] in non-responsive patients may therefore be justified. Patients with ulcerative 
jejunitis and EATL can have a significant risk of SB stricturing.  VCE should be used with 
caution therefore and a patency capsule should always be employed to reduce the incidence 
of capsule retention.  MRE has also been suggested to detect celiac related malignancies [322]. 
 
ESGE guidelines represent a consensus of best practice based on the available evidence at the time 
of preparation. They may not apply in all situations and should be interpreted in the light of specific 
clinical situations and resource availability. Further controlled clinical studies may be needed to 
clarify aspects of these statements, and revision may be necessary as new data appear. Clinical 
consideration may justify a course of action at variance to these recommendations. ESGE 
guidelines are intended to be an educational device to provide information that may assist 
endoscopists in providing care to patients. They are not rules and should not be construed as 
establishing a legal standard of care or as encouraging, advocating, requiring, or discouraging any 
particular treatment. 
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Abbreviations 
CD ǯ 
CECDAI ǯ 
CI  Confidence interval 
CECT Contrast enhanced computed tomography  
CTE Computed tomography enterography/enteroclysis 
CT Computed tomography 
CTA Computed tomography angiography 
DAE Device assisted enteroscopy 
DBE Double-balloon enteroscopy 
DY Diagnostic yield 
EATL Enteropathy associated T-cell lymphomas 
EBD Endoscopic balloon dilatation 
EGD Oesophagogastroduodenoscopy 
EMA Endomysial antibodies 
FAP Familial adenomatous polyposis 
FC Fecal calprotectin 
GFD Gluten free diet 
GIST Gastrointestinal stromal tumours 
HLA Human leucocyte antigen 
IBD Inflammatory bowel disease  
IBDU Inflammatory bowel disease unclassified 
ICCE International conference on capsule endoscopy 
IDA  Iron deficiency anaemia 
IOE  Intra-operative enteroscopy 
IY Incremental yield 
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MRE Magnetic resonance enterography/enteroclysis 
MRI Magnetic resonance imaging 
NPV Negative predictive value 
NSAIDs Non-steroidal anti-inflammatory drugs 
OR Odds ratio 
OGIB Obscure gastrointestinal bleeding 
PE Push enteroscopy 
PJS Peutz-Jeghers syndrome 
PPV Positive predictive value 
RCD Refractory celiac disease  
RCT Randomized controlled trial 
SB Small bowel 
SBFT Small-bowel follow-through 
SBT Small-bowel tumours 
SE Spiral enteroscopy 
VCE  Small bowel capsule endoscopy 
SBE Single-balloon enteroscopy 
tTG Tissue transglutaminase antibodies     
VA Villous atrophy 
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